Pfizer's top marketing officials sought to conceal trial results showing that Neurontin did not help patients with chronic nerve pain, according to internal documents and e-mails filed at a Boston court. The records were submitted as part of a possible class-action case against the drugmaker. Pfizer denied the claim, saying it reports study data "in an objective, accurate, balanced and complete manner."

Related Summaries